TG Therapeutics (NASDAQ:TGTX – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They currently have a $45.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 156.41% from the stock’s previous close. HC […]
Healthcare of Ontario Pension Plan Trust Fund boosted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 1,439.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 246,500 shares of the biopharmaceutical company’s stock after acquiring an additional 230,484 shares […]
ClariVest Asset Management LLC increased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 23.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 75,473 shares of the biopharmaceutical company’s stock after acquiring an additional 14,140 shares during the quarter. ClariVest Asset […]
TG Therapeutics (NASDAQ:TGTX – Get Free Report) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Friday. TGTX has been the subject of a number of other research reports. JPMorgan Chase & Co. lifted their price target on shares of TG […]
E Fund Management Co. Ltd. raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 170.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,010 shares of the biopharmaceutical company’s stock after acquiring an additional 27,744 shares during the […]